TY - JOUR
T1 - Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 1 Year of Follow-up
AU - Primary Tube Versus Trabeculectomy Study Group
AU - Gedde, Steven J.
AU - Feuer, William J.
AU - Shi, Wei
AU - Lim, Kin Sheng
AU - Barton, Keith
AU - Goyal, Saurabh
AU - Ahmed, Iqbal I.K.
AU - Brandt, James
AU - Gedde, Steven
AU - Banitt, Michael
AU - Budenz, Donald
AU - Lee, Richard
AU - Palmberg, Paul
AU - Parrish, Richard
AU - Vazquez, Luis
AU - Wellik, Sarah
AU - Werner, Mark
AU - Zink, Jeffrey
AU - Khatana, Anup
AU - Grover, Davinder
AU - Neelakantan, Arvind
AU - Barton, Keith
AU - El Karmouty, Ahmed
AU - Puertas, Renata
AU - Panarelli, Joseph
AU - Vinod, Kateki
AU - Goyal, Saurabh
AU - Lind, John
AU - Shields, Steven
AU - Lim, Kin Sheng
AU - Alaghband, Pouya
AU - Brandt, James
AU - Sherwood, Mark
AU - Khaimi, Mahmoud
AU - Sankar, Prithvi
AU - Ansari, Husam
AU - Miller-Ellis, Eydie
AU - Feldman, Robert
AU - Baker, Laura
AU - Bell, Nicholas
AU - Ahmed, Iqbal
AU - Williams, Donna
AU - Prum, Bruce
AU - Ramulu, Pradeep
AU - Jampel, Henry
AU - Feuer, William
AU - Londono, Luz
AU - Schiffman, Joyce
AU - Shi, Wei
AU - Silva, Yolanda
N1 - Publisher Copyright:
© 2018 American Academy of Ophthalmology
PY - 2018/5
Y1 - 2018/5
N2 - Purpose: To report 1-year treatment outcomes in the Primary Tube Versus Trabeculectomy (PTVT) Study. Design: Multicenter, randomized clinical trial. Participants: Two hundred forty-two eyes of 242 patients with medically uncontrolled glaucoma and no previous incisional ocular surgery, including 125 in the tube group and 117 in the trabeculectomy group. Methods: Patients were enrolled at 16 clinical centers and assigned randomly to treatment with a tube shunt (350-mm2 Baerveldt glaucoma implant) or trabeculectomy with mitomycin C (MMC; 0.4 mg/ml for 2 minutes). Main Outcome Measures: Intraocular pressure (IOP), glaucoma medical therapy, visual acuity, visual fields, surgical complications, and failure (IOP of more than 21 mmHg or reduced by less than 20% from baseline, IOP of 5 mmHg or less, reoperation for glaucoma, or loss of light perception vision). Results: The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20–5.60). Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001). Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06). Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03). Conclusions: Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study. Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up. The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.
AB - Purpose: To report 1-year treatment outcomes in the Primary Tube Versus Trabeculectomy (PTVT) Study. Design: Multicenter, randomized clinical trial. Participants: Two hundred forty-two eyes of 242 patients with medically uncontrolled glaucoma and no previous incisional ocular surgery, including 125 in the tube group and 117 in the trabeculectomy group. Methods: Patients were enrolled at 16 clinical centers and assigned randomly to treatment with a tube shunt (350-mm2 Baerveldt glaucoma implant) or trabeculectomy with mitomycin C (MMC; 0.4 mg/ml for 2 minutes). Main Outcome Measures: Intraocular pressure (IOP), glaucoma medical therapy, visual acuity, visual fields, surgical complications, and failure (IOP of more than 21 mmHg or reduced by less than 20% from baseline, IOP of 5 mmHg or less, reoperation for glaucoma, or loss of light perception vision). Results: The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20–5.60). Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001). Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06). Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03). Conclusions: Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study. Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up. The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.
UR - http://www.scopus.com/inward/record.url?scp=85042173156&partnerID=8YFLogxK
U2 - 10.1016/j.ophtha.2018.02.003
DO - 10.1016/j.ophtha.2018.02.003
M3 - Article
C2 - 29477688
AN - SCOPUS:85042173156
SN - 0161-6420
VL - 125
SP - 650
EP - 663
JO - Ophthalmology
JF - Ophthalmology
IS - 5
ER -